Healthcare provider profile · identity verified

Jyoti Saluja, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · BROOKFIELD, WI · NPI 1427023902

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jyoti Saluja, M.D. received $14.10 in general payments during 2025 across 1 reported records.

Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$14.10

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Exact Sciences Corporation Unresolved — no canonical attribution shown $14.10100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$14.101

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Cologuard Collection Kit
Normalized: cologuard collection kit
Device Exact Sciences Corporation $14.10 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium429124
LisinoprilLisinopril27175
Amlodipine BesylateAmlodipine Besylate27087
Losartan PotassiumLosartan Potassium26675
Levothyroxine SodiumLevothyroxine Sodium24965
HydrochlorothiazideHydrochlorothiazide21364
Metoprolol SuccinateMetoprolol Succinate15644
SimvastatinSimvastatin14040
Alendronate SodiumAlendronate Sodium12739
Sertraline HclSertraline Hcl12233
Rosuvastatin CalciumRosuvastatin Calcium9325
Metformin HclMetformin Hcl8932
Pantoprazole SodiumPantoprazole Sodium8723
EliquisApixaban7014
Metoprolol TartrateMetoprolol Tartrate6418
Pravastatin SodiumPravastatin Sodium6415
OmeprazoleOmeprazole6016
Potassium ChloridePotassium Chloride5820
AlprazolamAlprazolam5623
Escitalopram OxalateEscitalopram Oxalate5514
Metformin Hcl ErMetformin Hcl5217
FurosemideFurosemide4917
AtenololAtenolol4614
ValsartanValsartan4611
GabapentinGabapentin4514
AllopurinolAllopurinol4413
Bupropion XlBupropion Hcl4415
Montelukast SodiumMontelukast Sodium4211
XareltoRivaroxaban38suppressed
Citalopram HbrCitalopram Hydrobromide37suppressed
Fluoxetine HclFluoxetine Hcl3412
Albuterol Sulfate HfaAlbuterol Sulfate3315
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide33suppressed
Paroxetine HclParoxetine Hcl3211
EzetimibeEzetimibe31suppressed
Olmesartan MedoxomilOlmesartan Medoxomil30suppressed
LorazepamLorazepam29suppressed
SpironolactoneSpironolactone29suppressed
AbrysvoRsv Vacc, Pref A And Pref B/Pf2828
MirtazapineMirtazapine28suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl26suppressed
Hydralazine HclHydralazine Hcl25suppressed
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide25suppressed
Zolpidem TartrateZolpidem Tartrate2512
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid24suppressed
Boostrix TdapDiphth,pertuss(Acell),tet Vac2323
Trazodone HclTrazodone Hcl22suppressed
Donepezil HclDonepezil Hcl21suppressed
GlipizideGlipizide21suppressed
ClopidogrelClopidogrel Bisulfate20suppressed
ValacyclovirValacyclovir Hcl19suppressed
Doxazosin MesylateDoxazosin Mesylate18suppressed
Ipratropium BromideIpratropium Bromide18suppressed
Oxybutynin Chloride ErOxybutynin Chloride18suppressed
Clonidine HclClonidine Hcl17suppressed
DiazepamDiazepam17suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium17suppressed
LovastatinLovastatin17suppressed
Glipizide ErGlipizide16suppressed
Ropinirole HclRopinirole Hcl16suppressed
ShingrixVaricella-Zoster Ge/As01b/Pf1615
Duloxetine HclDuloxetine Hcl15suppressed
FamotidineFamotidine15suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1513
Enalapril MaleateEnalapril Maleate14suppressed
MyrbetriqMirabegron14suppressed
Pioglitazone HclPioglitazone Hcl14suppressed
AmoxicillinAmoxicillin13suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide13suppressed
Oxycodone HclOxycodone Hcl13suppressed
Advair HfaFluticasone Propion/Salmeterol12suppressed
Breo ElliptaFluticasone/Vilanterol12suppressed
Bupropion Hcl SrBupropion Hcl12suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl12suppressed
Hydroxyzine HclHydroxyzine Hcl12suppressed
MetronidazoleMetronidazole12suppressed
PrednisonePrednisone1211
SymbicortBudesonide/Formoterol Fumarate12suppressed
Amiodarone HclAmiodarone Hcl11suppressed
CarvedilolCarvedilol11suppressed
CelecoxibCelecoxib11suppressed
OlanzapineOlanzapine11suppressed
Quetiapine FumarateQuetiapine Fumarate11suppressed
Quetiapine Fumarate ErQuetiapine Fumarate11suppressed
Sildenafil CitrateSildenafil Citrate11suppressed
Tolterodine Tartrate ErTolterodine Tartrate11suppressed
Wixela InhubFluticasone Propion/Salmeterol11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $14.10 · 1 records Exact Sciences Corporation Cologuard Collection Kit
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error